Adapalene: The Retinoid You Can Buy Without a Prescription

Adapalene gel at 0.1% became the first topical retinoid sold without a prescription in the United States in 2016, and in May 2026 FDA approved a second nonprescription product, a combination of adapalene and benzoyl peroxide. The evidence behind it is strong for acne and thin for ageing, and its label asks pregnant and breastfeeding women to ask a doctor before use.

The claim this article tests is that adapalene is gentler than retinol. It covers the switch, why FDA accepted adapalene when other retinoids were kept behind a prescription, what the trials show for acne and for ageing, what the label says about the first weeks, and who the label says should not use it. It reports. It does not tell any reader whether to use it, and it issues no clearance.

The 2016 Switch

FDA's approval package for Differin Gel 0.1% records approval on 8 July 2016 of a supplement moving it from prescription to over-the-counter status. The Office Director's memo calls it a first-in-class prescription-to-OTC switch for a topical retinoid, for acne in adults and children 12 and older, at the same once-daily dosing as the prescription product. The Division Director's summary review adds that it was the first new active ingredient for acne available over the counter in more than 40 years. A Nonprescription Drugs Advisory Committee had voted 16 to 0 in favour on 15 April 2016.

FDA lists a maximal-use pharmacokinetic trial and three consumer studies. The label comprehension study had 586 people aged 12 to 70, and 96.5% of normal-literacy respondents answered "use once daily" correctly, against 86.9% of low-literacy respondents. FDA notes that the pregnancy and sun warnings were not tested, which "substantially limits the utility" of that study. A self-selection study of 293 pregnant and breastfeeding women found that 70% of the pregnant-only group said they would ask a doctor first, and the summary review calls that poor. In a 6-week actual-use study of 947 people, 14 chose to use the product while pregnant or breastfeeding. These studies tested understanding and use. They did not test acne clearance.

Not every reviewer agreed. FDA's Division of Dermatology and Dental Products recommended against the switch, citing the risk of pregnant women using it without supervision, and absorption that could rise on damaged skin, with other vitamin A products, or with heavy application. It noted a well-documented report of hepatitis from extreme use. The Division Director concluded that the risk was limited, and the Office Director agreed that the teratogenic risk was low.

FDA's approval letter of 22 May 2026 approves nonprescription use of an adapalene 0.1% and benzoyl peroxide 2.5% gel for acne in adults and children 12 and older. The letter approves tubes of 2, 15, 30 and 45 grams, and explains that it is limiting pack sizes because research links bigger packs with higher use. It follows the 2016 pattern, with the age floor unchanged.

Why Adapalene Was the One

FDA's memo describes adapalene as a naphthoic acid derivative and a third-generation retinoid with receptor binding that differs from first-generation retinoids such as isotretinoin, a known cause of birth defects in humans. A 2022 review of retinoids says adapalene acts selectively through two retinoic acid receptors, RAR-β and RAR-γ.

The case rested on exposure and track record. The maximal-use trial gave a safety margin of at least 70-fold against the teratogenic effects seen with high oral doses in animals. The safety database held 5,414 people exposed in trials, there were 20 years of marketing, and the sponsor estimated over 40 million people had been prescribed it. FDA found no case among its adverse-event reports that was consistent with retinoid embryopathy. As reasoning, adapalene was the first retinoid switched because its exposure margin and history were documented, not because it is the strongest retinoid.

What It Does for Acne

A 2019 systematic review of 54 trials (abstract) of topical retinoids approved in the US found them superior to vehicle on investigator global assessment, and judged the differences in efficacy between retinoids minor. It reported adverse events in 62% of people on tretinoin 0.05%, 19% on adapalene 0.1% and 40% on adapalene 0.3%, and concluded that adapalene has a superior tolerability profile. Its authors advise combining a retinoid with benzoyl peroxide.

An older meta-analysis of five randomised trials (abstract) of 900 people with mild to moderate acne found adapalene 0.1% gel equivalent to tretinoin 0.025% gel on total lesion count, quicker at week 1 for inflammatory and total lesions, and considerably better tolerated locally. Both are abstracts, the older one names the manufacturer's product, and neither states funding.

FDA's review adds the prescription label's own figures. Erythema, scaling, dryness, pruritus and burning occur in 10% to 40% of patients, and pruritus or burning right after application in about 20%. Our articles on getting rid of blackheads, on closed comedones and on adapalene with benzoyl peroxide cover how it fits among other acne options.

The Ageing Evidence

The 2022 review states that only tretinoin and tazarotene are approved among topical retinoids for photoaged skin, and that adapalene is used off-label for it. It describes three trials. A 9-month, randomised, masked study (Kang) in people with actinic keratoses and solar lentigines found adapalene 0.1% and 0.3% improved photoaged skin compared with vehicle, with acceptable tolerability. A 6-month open-label study of 0.3% gel in Chilean women had no control group. A 24-week trial of 128 people found 0.3% adapalene gel comparable to 0.05% tretinoin cream, with no statistically significant difference.

The review's summary is that tretinoin has the strongest evidence, and that adapalene and tazarotene "may be considered" as alternatives. Most of the adapalene work used the 0.3% gel, a higher strength than the over-the-counter 0.1%. The gap with acne is wide: the acne evidence is large and regulated, and the ageing evidence is a handful of trials. FDA expected some misuse, and its memo names "use for other conditions such as fine lines or wrinkles". The nonprescription label covers acne only. Our article on tretinoin and retinol sets out what separates a drug from a cosmetic.

The First Weeks

This section reports what the labels and FDA say and gives no regimen.

The Differin Gel 0.1% label and leaflet say that during the early weeks acne may appear to worsen before it improves, which they call normal, and that irritation is more likely in the first few weeks and when more than one acne medicine is used. They say it may take up to 3 months of once-daily use to see results, and that anyone who sees no improvement after 3 months should stop and ask a doctor. The leaflet says the product is not a spot treatment, that a moisturiser may help with dryness, that products containing alpha hydroxy or glycolic acids may worsen irritation, that waxing where it is applied may worsen irritation, and that irritation usually lessens after 4 weeks.

FDA's review reports erythema, scaling, dryness, pruritus and burning most often in the first month, decreasing in frequency and severity afterwards and reversible on stopping. In the actual-use study, half of participants reported at least one adverse event, most often headache, dry skin or erythema. Our article on purging versus breaking out covers how often a true flare appears in trials.

Who Should Not Use It, as Reported

The label says that anyone pregnant or breastfeeding should ask a doctor before use, and that use should stop, with a doctor asked, on becoming pregnant or planning to. The leaflet says that some other retinoids have been shown to cause birth defects and that there is no specific evidence adapalene 0.1% causes birth defects in humans when used topically as directed.

FDA judged the teratogenic risk low and kept the warning because it is good practice to discuss any medicine in pregnancy with a doctor. The UK Teratology Information Service summary (November 2022) reaches a different emphasis from the same facts. It says an increased risk of malformation is unlikely at therapeutic doses used as directed, and that because of the known teratogenicity of retinoids and inadequate pregnancy data for adapalene, its use during pregnancy cannot be recommended. It records one case report of anophthalmia after topical adapalene. Our article on skincare in pregnancy sets out where specialist bodies differ.

The 0.1% label says not to use it on damaged skin (cuts, abrasions, eczema, sunburn), or if allergic to adapalene or any ingredient, and to avoid contact with eyes, lips and mouth. It says children under 12 should ask a doctor. The 2026 combination label tightens the wording: it adds that people with very sensitive skin or sensitivity to benzoyl peroxide should not use it, tells those with other skin or medical conditions to ask a doctor, and says children under 12 should not use it.

The Figure Audited: "Adapalene Is Gentler Than Retinol"

Verdict: unproven as stated. Adapalene has been shown gentler than tretinoin, and no source opened compares it with retinol. Findings:

1. The comparisons are with tretinoin. The 900-person meta-analysis found better local tolerability for adapalene 0.1% than tretinoin 0.025%, and the 54-trial review found adverse events in 19% on adapalene 0.1% against 62% on tretinoin 0.05%. The 2022 review recommends adapalene and tazarotene as alternatives to tretinoin in sensitive skin.
2. Retinol is also milder than tretinoin. Our article on tretinoin and retinol reports a skin study in which tretinoin raised redness 3.7-fold against vehicle and retinol produced only trace redness. Both are gentler than tretinoin, and the sources opened do not put them side by side.
3. They are different kinds of product. Adapalene is a drug with a label and trials. The 2022 review says clinical efficacy studies are not required for cosmetic retinoid formulations, so "retinol" covers products of very different strength and design, with no single irritation profile.
4. Adapalene is not free of irritation. The prescription label puts adverse effects at 10% to 40%, and half of the actual-use participants reported one.
5. The limit. A head-to-head trial of adapalene and a retinol product may exist and not have been found.

Conclusion

Adapalene 0.1% was the first topical retinoid sold over the counter because its exposure margin and 20-year record were documented, and FDA followed in 2026 with the combination gel. For acne the evidence is substantial and shows adapalene to be better tolerated than tretinoin, not better than retinol. For ageing there are a few trials, mostly of the higher 0.3% strength. The label points to a slow start, irritation that eases, results over up to 3 months, and a pregnancy question for a doctor.

If you start any acne treatment, photographing the same area in the same light each week, in an app like Skinic or in an album, shows more than memory does about whether it is helping. For pregnancy, breastfeeding, or skin that reacts badly, ask your own clinician.